EP1667672A4 - Method for preventing and/or treating neurodegenerative diseases - Google Patents

Method for preventing and/or treating neurodegenerative diseases

Info

Publication number
EP1667672A4
EP1667672A4 EP04773691A EP04773691A EP1667672A4 EP 1667672 A4 EP1667672 A4 EP 1667672A4 EP 04773691 A EP04773691 A EP 04773691A EP 04773691 A EP04773691 A EP 04773691A EP 1667672 A4 EP1667672 A4 EP 1667672A4
Authority
EP
European Patent Office
Prior art keywords
preventing
neurodegenerative diseases
treating neurodegenerative
treating
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04773691A
Other languages
German (de)
French (fr)
Other versions
EP1667672A1 (en
Inventor
Yosuke Funakoshi
Ken Mizushima
Toshio Takakuwa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of EP1667672A1 publication Critical patent/EP1667672A1/en
Publication of EP1667672A4 publication Critical patent/EP1667672A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP04773691A 2003-10-03 2004-10-01 Method for preventing and/or treating neurodegenerative diseases Withdrawn EP1667672A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50795203P 2003-10-03 2003-10-03
JP2004174577 2004-06-11
PCT/JP2004/014893 WO2005032537A1 (en) 2003-10-03 2004-10-01 Method for preventing and/or treating neurodegenerative diseases

Publications (2)

Publication Number Publication Date
EP1667672A1 EP1667672A1 (en) 2006-06-14
EP1667672A4 true EP1667672A4 (en) 2010-02-10

Family

ID=34425431

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04773691A Withdrawn EP1667672A4 (en) 2003-10-03 2004-10-01 Method for preventing and/or treating neurodegenerative diseases

Country Status (3)

Country Link
EP (1) EP1667672A4 (en)
JP (2) JP5485497B2 (en)
WO (1) WO2005032537A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2072047A1 (en) * 2005-03-15 2009-06-24 Ono Pharmaceutical CO., LTD. Therapeutic agent for opthalmic disease
US8975298B2 (en) * 2005-06-27 2015-03-10 Ono Pharmaceutical Co., Ltd. Therapeutic agent for pain
JPWO2007046347A1 (en) * 2005-10-18 2009-04-23 小野薬品工業株式会社 Drugs for protecting motor nerves in patients with amyotrophic lateral sclerosis
EP1974727A4 (en) 2005-12-22 2009-12-09 Ono Pharmaceutical Co Therapeutic agent for acute cerebral infarct

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE163006T1 (en) * 1993-06-01 1998-02-15 Ono Pharmaceutical Co PENTANIC ACID DERIVATIVES
JP4706950B2 (en) * 2000-07-18 2011-06-22 小野薬品工業株式会社 Parkinson's disease therapeutic agent containing an astrocyte function improving agent as an active ingredient
KR100759771B1 (en) * 2000-07-18 2007-10-04 오노 야꾸힝 고교 가부시키가이샤 Agent for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient
CA2453478A1 (en) * 2001-07-18 2003-01-30 Ono Pharmaceutical Co., Ltd. Agent for treatment of cerebral ischemic diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ASANO T ET AL: "Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B", CURRENT DRUG TARGETS. CNS & NEUROLOGICAL DISORDERS, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, vol. 4, no. 2, 1 April 2005 (2005-04-01), pages 127 - 142, XP009124642, ISSN: 1568-007X *
FOR THE ARUNDIC ACID (ONO-2506) STROKE STUDY GROUP ET AL: "Safety and tolerability of arundic acid in acute ischemic stroke", JOURNAL OF NEUROLOGICAL SCIENCES, ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM, NL, vol. 251, no. 1-2, 21 December 2006 (2006-12-21), pages 50 - 56, XP025190710, ISSN: 0022-510X, [retrieved on 20061221] *
HONJO K ET AL: "Effects of ONO-2506 combined with thrombolytic therapy in a rat model of thrombotic focal cerebral ischemia", ABSTRACTS OF THE ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, vol. 27, no. 2, 10 November 2001 (2001-11-10), pages 2301, XP001539303, ISSN: 0190-5295 *
See also references of WO2005032537A1 *
TATEISHI NARITO ET AL: "Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits", JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM : OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF CEREBRAL BLOOD FLOW AND METABOLISM JUN 2002,, vol. 22, no. 6, 1 June 2002 (2002-06-01), pages 723 - 734, XP002552189 *

Also Published As

Publication number Publication date
JP5485497B2 (en) 2014-05-07
JP2012046543A (en) 2012-03-08
WO2005032537A1 (en) 2005-04-14
EP1667672A1 (en) 2006-06-14
JP2007507490A (en) 2007-03-29

Similar Documents

Publication Publication Date Title
GB2398810B (en) Well treatment method and system
EP1635763A4 (en) Method of treating neurodegenerative disease
EP1603548A4 (en) Method and composition for treating neurodegenerative disorders
EP1701664A4 (en) System and method for treating tissue
ZA200508427B (en) Methods for treating interleuking-6 related diseases
IL172590A0 (en) Method and system for treating wastewater
EP1684666A4 (en) Aneurysm treatment system and method
IL176126A0 (en) Electromagnetic treatment apparatus and method
AU2003303198A8 (en) Method for treating amyloid disease
MX263826B (en) Water treatment system and method
EP1636359A4 (en) Methods for treating pain
EP1683067A4 (en) Method for screening and treating disorders
ZA200604779B (en) Water treatment system and method
EP1651164A4 (en) Composition and method for treating neurological disorders
EP1655036A4 (en) Method for treating oncological diseases
EP1696877A4 (en) Methods for treating pain
EP1680073A4 (en) Compounds and method for treating cancer
IL164352A0 (en) Methods for treating tweak-related conditions
IL164219A0 (en) Method for treating and preventing hyparathyroidism
GB0609689D0 (en) Non-nucleotide compositions and method for treating pain
GB0323068D0 (en) Dewatering treatment system and method
GB2425617B (en) Device for preventing and treating myopia
ZA200604782B (en) Water treatment system and method
GB0311953D0 (en) Plant treatment method and means therefor
EP1575567A4 (en) Method and reagents for treating or preventing atherosclerosis and diseases associated therewith

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060331

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100112

17Q First examination report despatched

Effective date: 20110829

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20131017

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140228